A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF GENE THERAPY FOR CANAVAN DISEASE THROUGH ADMINISTRATION OF AN ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 9 BASED RECOMBINANT VECTOR ENCODING THE HUMAN ASPA GENE

Registry ID

CVN-102

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASPA THERAPEUTICS, INC, A SUBSIDIARY OF BRIDGEBIO PHARMA

Last update

2021-10-14

Conditions

• CANAVAN DISEASE

View on source registry